Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...

Source: Regeneron Pharmaceuticals, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Regeneron Pharma is currently 0.35% higher at $596.39 on Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Me, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction ...

Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different ...